ZA855425B - Use of 4h-1,4 benzothiazines for the prophylaxis and therapy of disorders of the respiratory tract,inflammations/rheumatism,thromboembolic disorders,ischaemias and infarcts,cardiac arrhythmias,arteriosclerosis and dermatoses,medicaments for this purpose,and active compounds contained in these medicaments - Google Patents

Use of 4h-1,4 benzothiazines for the prophylaxis and therapy of disorders of the respiratory tract,inflammations/rheumatism,thromboembolic disorders,ischaemias and infarcts,cardiac arrhythmias,arteriosclerosis and dermatoses,medicaments for this purpose,and active compounds contained in these medicaments

Info

Publication number
ZA855425B
ZA855425B ZA855425A ZA855425A ZA855425B ZA 855425 B ZA855425 B ZA 855425B ZA 855425 A ZA855425 A ZA 855425A ZA 855425 A ZA855425 A ZA 855425A ZA 855425 B ZA855425 B ZA 855425B
Authority
ZA
South Africa
Prior art keywords
medicaments
disorders
benzothiazines
ischaemias
infarcts
Prior art date
Application number
ZA855425A
Other languages
English (en)
Inventor
Gunter Benz
Gerd Fengler
Horst Meyer
Ekkehard Niemers
Volker B Fiedler
Mithat Mardin
Dieter Mayer
Elizabeth Perzborn
Friedel Seuter
Michael Hammond
William Taylor
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA855425B publication Critical patent/ZA855425B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA855425A 1984-07-19 1985-07-18 Use of 4h-1,4 benzothiazines for the prophylaxis and therapy of disorders of the respiratory tract,inflammations/rheumatism,thromboembolic disorders,ischaemias and infarcts,cardiac arrhythmias,arteriosclerosis and dermatoses,medicaments for this purpose,and active compounds contained in these medicaments ZA855425B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3426564A DE3426564A1 (de) 1984-07-19 1984-07-19 Verwendung von 4h-1,4-benzothiazinen bei der prophylaxe und therapie von erkrankungen der atemwege, entzuendungen/rheuma, thromboembolischen erkrankungen, ischaemien und infarkten, herzrhythmusstoerungen, arteriosklerose und dermatosen, arzneimittel zu diesem zweck sowie wirkstoffe, die in diesen arzneimitteln enthalten sind

Publications (1)

Publication Number Publication Date
ZA855425B true ZA855425B (en) 1986-02-26

Family

ID=6241006

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA855425A ZA855425B (en) 1984-07-19 1985-07-18 Use of 4h-1,4 benzothiazines for the prophylaxis and therapy of disorders of the respiratory tract,inflammations/rheumatism,thromboembolic disorders,ischaemias and infarcts,cardiac arrhythmias,arteriosclerosis and dermatoses,medicaments for this purpose,and active compounds contained in these medicaments

Country Status (6)

Country Link
EP (1) EP0174458A1 (fr)
JP (1) JPS6144883A (fr)
AU (1) AU4477385A (fr)
DE (1) DE3426564A1 (fr)
IL (1) IL75824A0 (fr)
ZA (1) ZA855425B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX159669A (es) * 1983-12-12 1989-08-02 Ciba Geigy Ag Procedimiento para la preparacion de derivados de acilamida
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4305080A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Verfahren zur Herstellung von Azaphenothiazinen
US5994349A (en) * 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
WO2000071528A1 (fr) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides et leur utilisation en tant que ligands des recepteurs cerebraux gaba

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO832663L (no) * 1982-08-04 1984-02-06 Bayer Ag 4h-1,4-benzothiazin-derivat, fremgangsmaate til deres fremstilling og deres anvendelse som laegemiddel, fortilsetningsstoffer og konserveringsmiddel
DE3229121A1 (de) * 1982-08-04 1984-02-09 Bayer Ag, 5090 Leverkusen 4h-1,4-benzothiazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3229122A1 (de) * 1982-08-04 1984-02-09 Bayer Ag, 5090 Leverkusen Anellierte 4h-1,4-benzothiazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
IL75824A0 (en) 1985-11-29
AU4477385A (en) 1986-01-23
JPS6144883A (ja) 1986-03-04
EP0174458A1 (fr) 1986-03-19
DE3426564A1 (de) 1986-01-30

Similar Documents

Publication Publication Date Title
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
CY1727A (en) Medicaments for the treatment of emesis
CA2260145A1 (fr) Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
NO864336L (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte-n-(3-(1,2,4-triazolo(4,3-6)pyridazin-6-yl)fenyl)alkanamider,-karbamater og -urinstoffer.
IT8120629A0 (it) Composti morfolinici, loro preparazione e impiego per il trattamento della cavita' orale.
EG18730A (en) Substituted tetralin, chromans and related compounds in the treatment of asthma, arthritis and related diseases
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
DE3062981D1 (en) Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
GR3032541T3 (en) Use of norastemizole for the treatment of allergic disorders.
EP0179808A4 (fr) Composition pharmaceutique approprie pour traitement ou de prophylaxie d'affections cardiaques.
EP0185210A3 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
HK36693A (en) Use of ketone derivatives in the treatment of cognitive disorders
DE3369682D1 (en) 2-substituted 1-aminoalkyl-1,2,3,4-tetrahydro-beta-carbolines, their preparation and use as medicaments
GR3030150T3 (en) Use of Human Interferon-Beta 2A for the preparation of medicaments
ZA855425B (en) Use of 4h-1,4 benzothiazines for the prophylaxis and therapy of disorders of the respiratory tract,inflammations/rheumatism,thromboembolic disorders,ischaemias and infarcts,cardiac arrhythmias,arteriosclerosis and dermatoses,medicaments for this purpose,and active compounds contained in these medicaments
ZA891366B (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias
IL65184A0 (en) Preparation for the treatment of oral diseases,comprising glycyrrhizin
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
GB2220352B (en) Medicaments for the treatment of emesis
EP0689839A3 (fr) Utilisation d'inhibiteurs de l'adenosine triphosphatase pour la fabrication d'un médicament pour le traitement de maladies associées au peptide beta-amyloid
AU4476089A (en) Use of azepinone derivatives for the treatment of respiratory tract disorders
GB2216414B (en) Medicaments for the treatment of emesis
ZA86365B (en) Use of sulphanyldihydropyridines as medicaments for the treatment of asthma
WO1986006960A3 (fr) Utilisation de nicorandile ou de pinacidile dans le traitement de maladies vasculaires peripheriques